Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : PJ August 2015 online

Sort by: Newest first Oldest first A-Z Z-A

  • Voltarol discontinuations Subscription

    8 SEP 2015 10:57

    Novartis is discontinuing several different Voltarol products (diclofenac), which will become unavailable once stock is exhausted. Products that are already out of stock are: Voltarol dispersible tablets 50mg (3x7 pack), Voltarol Retard 100mg (2x14 pack) and Voltarol SR 75mg (4x14 pack). It is estimated that Voltarol tablets 50mg (9x10 pack) will go out of stock in October 2016, Voltarol tablets 50mg (1x10 hospital pack) will go out of stock in January 2016, Voltarol SR 75mg (2x14 pack) ...

  • Adcirca contraindicated with riociguat Subscription

    8 SEP 2015 10:55

    The summary of product characteristics for Adcirca (tadalafil; Eli Lilly) now states that the co-administration of phosphodiesterase 5 (PDE5) inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it could lead to symptomatic hypotension.  

  • Imbruvica side effects Subscription

    8 SEP 2015 10:38

    The summary of product characteristics for Imbruvica (ibrutinib; Janssen Cilag) has been updated to reflect that there have been some cases of fatal major haemorrhagic events, including gastrointestinal bleeding, intracranial haemorrhage and haematuria. 

  • The meningococcal group B (MenB) Bexsero vaccine will be added to the NHS childhood immunisation programme in England from 1 September 2015. In the image, a child is vaccinated

    Young children receiving new meningitis vaccine can benefit from paracetamol Subscription

    28 AUG 2015 15:42
    Comments (1)

    The meningococcal group B (MenB) Bexsero vaccine will be added to the NHS childhood immunisation programme in England from 1 September 2015.

  • Edoxaban and vedolizumab recommended by NICE Subscription

    27 AUG 2015 9:39

    The National Institute for Health and Care Excellence has recommended edoxaban (Lixiana; Daiichi Sankyo) as an option for treating and preventing recurrent deep vein thrombosis or pulmonary embolism. Edoxaban is an oral anticoagulant that directly inhibits factor X (factor Xa), which is a key component in the formation of blood clots. In addition, vedolizumab (Entyvio; Takeda) has been recommended as a possible option for adults with moderate to severe ...

  • Daklinza treatment regimen Subscription

    25 AUG 2015 15:42

    Daklinza (daclatasvir; Bristol-Myers Squibb) can now be used for 12 weeks, rather than 24 weeks, in combination with sofosbuvir to treat patients with chronic hepatitis C genotype 3. 

  • Increased blood pressure with Dianette Subscription

    25 AUG 2015 15:40

    The summary of product characteristics for Dianette (cyproterone acetate and ethinylestradiol; Bayer) now includes increased blood pressure as an adverse effect. 

  • Caneston Bifonazole interaction with warfarin Subscription

    25 AUG 2015 15:38

    The summary of product characteristics for Canesten Bifonazole Once Daily 1% w/w Cream (Bayer) now warns of a potential interaction with warfarin. Limited data suggests that an interaction between topical bifonazole and warfarin may be possible, leading to increases in INR [international normalised ratio]. If bifonazole is used in a patient on warfarin therapy they should be appropriately monitored. Closer monitoring may be ...

  • Levemir now indicated for children aged one year and over Subscription

    25 AUG 2015 15:36

    Levemir (insulin detemir; Novo Nordisk) is indicated for treatment of diabetes mellitus in adults, adolescents and children aged one year and over. It was previously licensed for children aged over two years. 

  • Taking oral contraceptives (OCs) may benefit women who have inflammatory arthritis, according to research. In the image, a woman holds a blister pack of oral contraceptives

    Oral contraceptives may improve inflammatory arthritis outcomes Subscription

    24 AUG 2015 10:03

    Taking oral contraceptives may benefit women who have inflammatory arthritis, according to research published in Arthritis Care and Research.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.